• 23 January 2017

    Eli Lilly aims to dominate the migraine market

    In January 2017, Eli Lilly acquired US-based specialty company CoLucid for approximately $960m, a 33% premium over CoLucid’s share price. The value of the deal highlights the substantial commercial opportunity...

  • 7 December 2016

    Inclisiran offers hope for dyslipidemia patients

    Therapy inclisiran (formerly ALN-PCSsc) is currently being developed by The Medicines Company and Alnylam Pharmaceuticals. It specifically targets the PCSK9 messenger ribonucleic acid (mRNA), inhibiting protein synthesis.

Go Top